CLINICAL MICROBIOLOGY REVIEWS临床微生物学评论
CLINICAL MICROBIOLOGY REVIEWS(英文缩写 CLIN MICROBIOL REV),ISSN 0893-8512,eISSN 1098-6618,中文译名:临床微生物学评论 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 50.129 | Q1 |
| 2022 | 36.800 | Q1 |
| 2023 | 19.000 | Q1 |
| 2024 | 19.300 | Q1 |
| 2025 | 20.700 | Q1 |
CLINICAL MICROBIOLOGY REVIEWS 最新收录文献
-
1. {"_":"Re-emergence of species: epidemiology and pathogenesis.","i":["Brucella"]}
1. {“_”：“物种的重新出现：流行病学和发病机制。”，“i”：[“布鲁氏菌”]}PMID:日期:2026-09-30SUMMARY spp. are highly adapted intracellular bacterial pathogens that remain a substantial global cause of zoonotic disease. The globally distributed species , , , and account for the majority of human infections, reflecting their efficient transmission across animal hosts, and their exceptional capacity to survive and replicate within the intracellular niche. Although animal infections are often clinically silent, human brucellosis can exhibit persistent intracellular infection and relapsing fever. Growing genomic data highlight expanding species diversity, including and marine . Progress in elucidating the intracellular life cycle of , including the maturation of -containing vacuoles, immune evasion strategies, and the role of the type IV secretion system, has refined our understanding of disease pathogenesis across hosts. At the same time, expanding molecular surveillance, global minimum-spanning-tree analyses, and One Health epidemiology have clarified transmission pathways among livestock, dogs, wildlife, and humans, revealing both cross-species connectivity and geographical hotspots of emergence. Given the limitations of existing livestock vaccines and the absence of human or canine vaccines, diverse next-generation platforms are now advancing toward translational evaluation. Unlike prior reviews focused primarily on livestock brucellosis or classical species, this review integrates emerging canine and marine lineages with advances in genomics, intracellular pathogenesis, and next-generation vaccine strategies within a unified One Health framework. In this review, we synthesize global trends in species diversity, zoonotic emergence, mechanisms of intracellular pathogenesis, and the status of current and experimental vaccines, while highlighting the One Health interventions needed to disrupt transmission and advance toward comprehensive brucellosis control.
-
2. HIV therapeutics in 2026.
2. 2026年的HIV治疗PMID:日期:2026-09-30The treatment and prevention of HIV have undergone significant transformations in the 16 years since the last major review of HIV therapeutics published in ASM's (A. M. N. Tsibris and M. S. Hirsch, J Virol 84:5458-5464, 2010, https://doi.org/10.1128/jvi.02524-09). First-generation antiretroviral medications, many now discontinued, have been replaced by integrase strand transfer inhibitor-based regimens that offer superior efficacy, higher genetic barriers to resistance, and the convenience of a single-tablet fixed-dose combination. Dolutegravir and bictegravir are now the anchors of most first-line therapies worldwide, and two-drug and nucleoside reverse transcriptase inhibitor (NRTI)-sparing strategies have emerged, allowing for simplification of treatment of patients who had been previously on complex regimens. The most consequential recent advance, though, has been the introduction of long-acting injectable medications, including cabotegravir-rilpivirine for treatment, standalone cabotegravir for pre-exposure prophylaxis (PrEP), and lenacapavir, a first-in-class capsid inhibitor for both treatment and PrEP. For people with multidrug-resistant HIV, new agents including fostemsavir, ibalizumab, and lenacapavir have made virologic suppression achievable in virtually all heavily treatment-experienced patients. An investigational and emerging pipeline that includes third-generation integrase inhibitors, nucleoside reverse transcriptase translocation inhibitors, maturation inhibitors, and broadly neutralizing antibodies promises further expansion of HIV therapeutic options. These advances, however, come with potential challenges, including emergent resistance to long-acting agents, metabolic consequences of lifelong therapy in an aging population, persistent inequities in global access to newer agents, and often insufficient safety data in pregnancy and breastfeeding. This review provides a clinical assessment of the current antiretroviral options, from legacy agents to investigational therapies, with attention to the resistance, implementation, and special population considerations that will shape HIV practice in the future.
-
4. A new era of dermatophytes: emerging species, new risk factors, and taxonomic change.
4. 皮肤癣菌的新时代：新物种、新风险因素和分类变化PMID:日期:2026-09-11SUMMARYThe traditional landscape of dermatophyte infections has changed over the past decade. The emergence and global expansion of have highlighted the impact of irrational and uncontrolled antifungal and topical corticosteroid use, presented treatment challenges, and highlighted the deficiencies of currently available diagnostic methods. genotype VII, which has until recently been associated with animal reservoirs, is now associated with human-to-human transmission and is frequently related to sexual transmission. Infections associated with emerging dermatophytes are notable for atypical presentations that may include widespread, inflamed lesions, terbinafine resistance, and frequent relapse. The classic presentation of tinea lesions is frequently obscured by the application of topical corticosteroids, leading to delays in clinical recognition, diagnosis, and appropriate treatment, perpetuating further misuse of topical medications. Deep or invasive dermatophytoses, including Majocchi's granuloma, may occur in immunocompromised patients. The introduction of matrix-assisted laser desorption/ionization-time of flight mass spectrometry and molecular detection of dermatophytes has improved the diagnostic landscape for dermatophytes. However, currently, most assays do not specifically detect or genotype VII, hindering the diagnosis and surveillance. Sequencing of the internal transcribed spacer (ITS) region is required for definitive identification. Terbinafine and azole resistance is common in and increasingly being reported for other species. While nomenclatural changes have been introduced and debated over many decades, the last decade has seen the introduction of new genera, e.g., and . An overview of currently recognized dermatophyte species, complexes, and genera is presented here, describing phylogenetic, ecological, and biochemical relatedness. The ethical conundrum of the name is also discussed.
-
5. Emerging tick-borne viral diseases in East Asia: pathology-driven insights into pathogenesis and disease causality.
5. 东亚新出现的蜱传病毒性疾病：病理学驱动的发病机制和疾病因果关系的见解PMID:日期:2026-09-03SUMMARYTick-borne viral infections have emerged as a significant and growing public health concern. In East Asia, severe fever with thrombocytopenia syndrome (SFTS) has served as a prototypical disease in which pathological analyses have substantially advanced the understanding of disease pathogenesis. SFTS is characterized by profound immune dysregulation driven by viral tropism for plasmablast-lineage B cells, leading to cytokine storm and hemophagocytic syndrome. Complementary analyses of human clinical specimens and experimental animal models, including cats and ferrets, have provided critical insights into the immunopathogenesis of SFTS. The recent identification of additional tick-borne viruses, including Oz virus (OZV), Yezo virus (YEZV), and Alongshan virus (ALSV), has further expanded the spectrum of emerging infections in this region. Notably, pathological investigation of a fatal human case of OZV infection demonstrated direct viral localization within cardiomyocytes, establishing a causal link between infection and fulminant myocarditis and highlighting a distinct organ-specific pathogenic mechanism. Despite the advances in genomic technologies that enable rapid detection of novel viruses, establishing causal relationships between viral presence and disease remains a major challenge. Tissue-based pathological approaches, particularly localization of viral components, are, therefore, essential for defining disease mechanisms and confirming etiological roles. This review provides a comprehensive synthesis of tick-borne viral infections in East Asia, with particular emphasis on Japan, integrating pathological, virological, and clinical perspectives. It also identifies key knowledge gaps and underscores the importance of a synergistic One Health framework that incorporates both human and veterinary pathology to advance the understanding and control of these emerging diseases.
-
6. Human vascular pythiosis: pathogenesis, diagnosis, and evidence-informed management.
6. 人类血管性脓毒症：发病机制、诊断和循证治疗PMID:日期:2026-09-03Human vascular pythiosis is a rare, life-threatening angioinvasive infection caused predominantly by the oomycete . Unlike ocular or cutaneous pythiosis, the vascular form is defined by arterial wall invasion, long-segment thrombosis, limb ischemia, aneurysmal complications, and high risks of amputation and death. Although is broadly distributed in freshwater environments, reported human vascular disease remains concentrated in Thailand, indicating that exposure alone is insufficient for disease development. Available evidence supports a multifactorial model centered on repeated freshwater exposure and host susceptibility, particularly hemoglobinopathies and iron dysregulation, while the rarity of comparable vascular disease elsewhere remains unexplained. Because vascular-specific mechanistic data are limited, evidence from animal pythiosis, nonvascular human disease, environmental studies, genomic analyses, and experimental models must be interpreted selectively and linked explicitly to vascular pathogenesis, diagnosis, or management. Infection usually begins at sites of skin disruption after freshwater exposure and progresses through soft tissue and perivascular planes into the arterial wall. Longitudinal intramural extension, rather than typical hematogenous dissemination, explains long-segment arterial occlusion, proximal progression, and relapse after incomplete source control. Diagnosis requires early suspicion, serology, vascular imaging, and tissue-based confirmation. Management depends on prompt and complete surgical removal of infected arterial tissue, supported by adjunctive protein-synthesis-inhibiting antibacterial therapy, particularly when residual disease is suspected. Conventional antifungals have limited activity, and antigen immunotherapy remains historically important but of uncertain independent benefit. Earlier recognition, better surgical-margin assessment, standardized diagnosis, and prospective treatment data are needed.
-
7. Highly pathogenic avian influenza viruses in mammals: host-range expansion and implications of milk-borne viral shedding.
7. 哺乳动物中的高致病性禽流感病毒：宿主范围的扩大和乳传病毒脱落的影响PMID:日期:2026-08-31SUMMARYHighly pathogenic avian influenza (HPAI) viruses, especially subtype H5N1, have caused major outbreaks in poultry and serious human infections since the first description of "fowl plague" in 1878. Over time, these viruses have expanded their host range, causing huge losses in domestic poultry, spreading among wild bird populations, and occasionally infecting humans. Understanding how influenza viruses adapt and cross species barriers depends on analyzing their fundamental molecular characteristics. Key features such as the polybasic cleavage site within the hemagglutinin protein and the distinctive "1+7" ribonucleoprotein complex, which consists of a single polymerase core surrounded by seven RNA segments, enhance viral replication and broaden host range. Despite decades of intervention, including lessons from the 1997 Hong Kong outbreak and the continued global circulation of clade 2.3.4.4b, HPAI remains difficult to control. A major shift occurred in 2024, when H5N1 was detected in U.S. dairy cattle. This was the first confirmed instance of viral shedding into milk from a mammalian host, suggesting a new potential route of transmission beyond the traditional avian reservoirs. This review unites historical milestones, structural insights, epidemiological data, and recent cross-species findings to better define the current landscape of risk and transmission. We further discuss economic, public health, and agricultural impacts of these developments, particularly the 2024 cattle cases, and underscore the urgent need for an integrated One Health approach to better manage the growing risks posed by HPAI viruses.
-
8. {"_":" disease in Southeast Asia: microbiology and epidemiology in humans and pigs.","i":["Streptococcus suis"]}
PMID:日期:2026-08-11SUMMARY is a swine pathogen causing significant economic losses and an important zoonotic agent in humans. Southeast Asia is a high-incidence region, where infection is strongly linked to consumption of raw or undercooked pork and occupational exposure to pigs or pork products. Thailand and Vietnam report the highest case numbers, with additional cases in Indonesia (Bali), Malaysia, Singapore, Lao PDR, and Cambodia. Serotype 2 predominates in both humans and pigs, followed by serotype 14, while other serotypes (1, 4, 5, 7, 9, 16, 24, and 31) are also reported in humans. In pigs, a broader serotype range is observed, including 1 or 14, 2, 4, 5, 6, 7, 8, 9, 15, 16, 18, 21, 29, 31, and nontypeable strains. Human infections involve multiple clonal complexes (CC1, CC16, CC25, CC28, CC94, CC104, CC233, CC221/234, and CC1688), several overlapping with porcine lineages. The region is also challenged by increasing antimicrobial resistance, with rising non-susceptibility to macrolides and tetracyclines and occasional reduced susceptibility to penicillin. Diagnostic limitations due to misidentification, limited molecular tools, and reliance on conventional methods further complicate surveillance. The economic burden is substantial, driven by swine losses, treatment costs, outbreaks, and severe human disease. Vaccination remains suboptimal due to limited protection against genetically and antigenically diverse strains across serotypes and CCs. An urgent One Health approach integrating animal health, food safety, and human health is needed to monitor dynamics. Control measures should target farms, slaughterhouses, and retail markets while promoting community-accepted behavioral changes to reduce transmission risk.
-
9. {"_":"From decline to resurgence: current perspectives on .","i":["Mycoplasma pneumoniae"]}
9. {"_":"从衰落到复苏：当前关于","i":["肺炎支原体"]}的视角PMID:日期:2026-08-06pneumonia (MPP) is an acute respiratory infection caused by (MP) and constitutes the primary cause of community-acquired pneumonia (CAP) among children aged 5 years and older in China. The clinical manifestations of MP-associated respiratory disease in children are diverse, ranging from mild upper respiratory symptoms to life-threatening pneumonia. Notably, during the implementation of nonpharmaceutical interventions (NPIs) aimed at curbing SARS-CoV-2 transmission, there was a significant decline in MP infection rates. However, a pronounced global resurgence of MP infections was documented in 2023-2024. The increasing global prevalence of macrolide resistance, particularly in China, coupled with limited alternative antibiotic options for children, increasing rates of coinfections, and the absence of a preventive vaccine, collectively exacerbate treatment challenges and increase the disease burden. Furthermore, the insufficient availability of MP nucleic acid testing and antimicrobial resistance surveillance in primary healthcare settings, coupled with the absence of a comprehensive epidemiological monitoring network, results in a vicious public health cycle. Recent advances and emerging genomic data have provided new insights into its pathogenesis and clinical management. Therefore, in this narrative review, we aim to (i) synthesize the current understanding of the etiological characteristics of MP and the present status of MPP diagnosis and treatment; (ii) analyze recent advances and drivers behind the global resurgence of MP infections; and (iii) propose integrated prevention and control strategies to increase the recognition of MPP and prevent unanticipated outbreaks.
-
10. Advancement of LAMP technologies for rapid and accurate diagnosis of infectious diseases.
10. LAMP技术的进步，用于快速准确地诊断传染病PMID:日期:2026-08-04SUMMARYLoop-mediated isothermal amplification (LAMP) is a type of isothermal nucleic acid amplification test (NAAT). Compared to more traditional NAATs, like polymerase chain reaction (PCR), LAMP is run at one consistent temperature, utilizes four to six primers, and uses polymerase. Some advantages that are provided by these differences are that LAMP has lower equipment requirements, resiliency to common PCR inhibitors, and a rapid time to result. Unfortunately, some disadvantages are also present due to these differences, such as more challenging primer design, reduced multiplexing capability, and difficulty with quantitation. Due to its unique characteristics, LAMP has proven to be an attractive option for molecular diagnostics in resource-limited, point-of-care, and near-patient testing settings. However, its adoption in clinical settings remains limited compared to its widespread use in research. In this review, we cover various detection methods within LAMP, recent advancements including extraction, multiplexing, and quantification, as well as key clinical applications of LAMP from a syndromic perspective. We also explore the commercial potential of LAMP and how it can be leveraged in resource-constrained settings and clinical laboratories, especially where early, affordable, and rapid diagnosis is essential.